Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

901. Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer" [Eur Urol 2010;58:803-15]. (Abstract)

Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer" [Eur Urol 2010;58:803-15]. 28065364 2019 11 20 1873-7560 59 3 2011 Mar European urology Eur. Urol. Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer" [Eur Urol 2010;58:803-15]. 476 S0302-2838(10)01144-9 10.1016/j.eururo.2010.11.042

2017 European Urology

902. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ten randomised clinical trials. (Full text)

First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ten randomised clinical trials. The aim of this study is to systematically evaluate all available treatment options in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). We systematically searched PubMed, EMBASE, and the Cochrane libraries up to 1 March 2016 for peer-reviewed publications on randomised clinical trials

2017 BJU international PubMed abstract

903. Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App (Full text)

Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostate cancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both (...) practitioners and patients for a variety of purposes.The impetus of the study was to design, develop, and assess a smartphone app for prostate cancer screening, based on the Rotterdam Prostate Cancer Risk Calculator (RPCRC).The results of the Rotterdam arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC) study were used to elaborate several algorithms that allowed the risk of prostate cancer to be estimated. A step-by-step workflow was established to ensure that depending

2017 JMIR cancer PubMed abstract

904. Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. (Full text)

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR (...) with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p > 0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p

2017 Journal of immunology research PubMed abstract

905. What Are the Links of Prostate Cancer with Physical Activity and Nutrition? : A Systematic Review Article. (Full text)

What Are the Links of Prostate Cancer with Physical Activity and Nutrition? : A Systematic Review Article. Prostate cancer (PCa) is the second most common malignancy in men worldwide. The purpose of this study was to provide a brief synthesis the current knowledge for the effects of physical activity (PA) and nutrition on PCa risk.A systematic review of English languages reviews, meta-analysis, and original articles published from 2009 to 2015 extracted from the following websites: MEDLINE, Web (...) and/or fruit intake with PCa risk was reported in eight of 13 papers. The effect of meat/fat intake on PCa was estimated in four articles finding increased risk. There was heterogeneity between studies, and findings are inconsistent.Physical activity does not significantly reduce the risk of PCa; however, vigorous exercise may reduce the risk of aggressive tumor. Besides, there is a lack of definitive evidence supporting the preventive role of diet against PCa. Due to many other benefits of regular

2017 Iranian journal of public health PubMed abstract

906. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. (Full text)

Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. The European Randomised Study of Screening for Prostate Cancer trial has shown a 21% reduction in prostate cancer (PC) mortality with prostate-specific antigen (PSA)-based screening. Sweden used a 2-yr screening interval and showed a larger mortality reduction than Finland with a 4-yr (...) between the Finnish and Swedish centres and estimated the impact of different screening protocols.If the Swedish screening protocol had been followed in Finland, 122 additional PC cases would have been diagnosed at screening, 84% of which would have been low-risk cancers, and four leading to PC death. In contrast, if a lower PSA threshold had been applied in Finland, at least 127 additional PC would have been found, with 19 PC deaths.The small number of deaths among cases that would have been

2017 European urology focus Controlled trial quality: uncertain PubMed abstract

907. Prostate Cancer Screening

you like to save your information to view later? Create an account and sign in to keep your Decision box results and view them later. You can also: Continue without an account and print your profile when the process is completed Prostate Cancer Screening Men between the ages of 55 and 69 with at least a 10-year life expectancy. Screening is appropriate for people who do not carry a disease that affects their life expectancy. The prostate-specific antigen (PSA) blood test is used to screen men (...) Prostate Cancer Screening Boîte à décision | Box details Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. I do not have an account Provide some personal information and create a user account allowing to save your Decision box results and view them later. You can also: I already have an account Please enter your email address and password to access your profile and consult your decision boxes. Email

2017 Cancer Council Australia

908. In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance

In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In localised prostate cancer, radical prostatectomy was associated

2017 Evidence-Based Medicine

909. Canadian Urological Association recommendations on prostate cancer screening and early diagnosis

Canadian Urological Association recommendations on prostate cancer screening and early diagnosis CUAJ • October 2017 • Volume 11, Issue 10 © 2017 Canadian Urological Association CUA GUIDELINE 298 Cite as: Can Urol Assoc J 2017;11(10):298-309. http://dx.doi.org/10.5489/cuaj.4888 See related editorial on page 295 Introduction Prostate cancer remains the most commonly diagnosed non- cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In 2016 (...) , an estimated 21 600 men were diagnosed with prostate cancer and 4000 men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over- treatment of indolent disease remains a significant challenge. Several professional associations have developed guidelines on prostate cancer screening and early diagnosis

2017 Canadian Urological Association

910. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update.

of the guideline. This guideline updates a previous version: Rodrigues G, Yao X, Loblaw A, Brundage M, Chin J, Genitourinary Cancer Disease Site Group. Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer. Toronto (ON): Cancer Care Ontario (CCO); 2012 Oct 31. 55 p. (Evidence-based series; no. 3-10). [165 references] This guideline meets NGC's 2013 (revised) inclusion criteria. UMLS Concepts ICD9CM (185), (60.5) MSH , , , , , , , , MTH , , , , , , , , PDQ , , , , SNOMEDCT_US (...) brachytherapy; no recommendation can be made for or against using 131 Cs or HDR monotherapy. Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease. None provided Prostate cancer Treatment Nuclear Medicine Oncology Radiation Oncology Surgery Urology Physicians To provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of brachytherapy for patients with prostate cancer that includes

2017 National Guideline Clearinghouse (partial archive)

911. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline.

; Evidence Level: Grade B ) Effective shared decision making in prostate cancer care requires clinicians to inform patients about immediate and long-term morbidity or side effects of proposed treatment or care options. ( Clinical Principle ) Clinicians should inform patients about suitable clinical trials and encourage patients to consider participation in such trials based on eligibility and access. ( Expert Opinion ) Care Options by Cancer Severity/Risk Group Very Low-/Low-Risk Disease Clinicians (...) . ( Expert Opinion ) Intermediate-Risk Disease Clinicians should consider staging unfavorable intermediate-risk localized prostate cancer patients with cross sectional imaging (CT or magnetic resonance imaging [MRI]) and bone scan. ( Expert Opinion ) Clinicians should recommend radical prostatectomy or radiotherapy plus ADT as standard treatment options for patients with intermediate-risk localized prostate cancer. ( Strong Recommendation; Evidence Level: Grade A ) Clinicians should inform patients

2017 National Guideline Clearinghouse (partial archive)